UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
STOMP
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
- CELMoD
- SINE
- Phase 1/2
- Has results
Accepting patients
Iberdomide vs. Observation Post Ide-Cel CAR-T
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
Etentamig
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Not yet accepting
P-BCMA-ALLO1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
- Has results
Accepting patients
Isatuximab in Frail Patients
Isatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
Registry of Older Patients With Cancer
Carolina Senior: UNC Registry for Older Cancer Patients
- Patient Registry
- Observational Trial
Accepting patients
Tissue, Blood, and Body Fluid Sample Collection
Tissue Procurement For Hematolymphoid Conditions
- Observational Trial
Accepting patients
DISCOVERY
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Randomization
Not currently accepting
Daratumumab Combination Induction
An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation
- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2